Challenges associated with implementing immune checkpoint blockade in SCLC

Giuseppe Lamberti, MD, University Hospital of Bologna, Bologna, Italy, talks on challenges associated with implementing immune checkpoint inhibitors in small cell lung cancer (SCLC) Current data suggests that immune checkpoint inhibitors are benefitting a subgroup of patients with SCLC. However, the main challenge is deciphering which subgroup of patients are benefitting, which has yet to be elucidated due to the current lack of biomarkers. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.